The Cost-effectiveness analysis of HMGA2 prognostic test for AML is now published
Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.
Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.